This report provides information on the therapeutic development for Oligodendroglioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oligodendroglioma. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Oligodendroglioma.
- A review of the Oligodendroglioma products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oligodendroglioma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Oligodendroglioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oligodendroglioma pipeline depth and focus of Oligodendroglioma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Oligodendroglioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oligodendroglioma 9
Oligodendroglioma Therapeutics under Development by Firms 11
Oligodendroglioma Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Oligodendroglioma Therapeutics - Products under Development by Firms 18
Oligodendroglioma Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Oligodendroglioma Therapeutics Development 21
AstraZeneca PLC 21
Tocagen Inc 21
Oligodendroglioma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AZD8055 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CPT-11 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Tandutinib + Bevacizumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Tandutinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Gleevec - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
procarbazine hydrochloride - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Temozolomide + Busulfan + Thiotepa - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Temozolomide + Busulfan + Thiotepa - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 40
Temozolomide + Radiation Therapy - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Topotecan hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Filgrastim + Sargramostim + Cyclophosphamide + Thiotepa + Peripheral Blood Stem Cell Transplantation/Autologous Bone March row Transplantation - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Filgrastim + Sargramostim + Cyclophosphamide + Thiotepa + Peripheral Blood Stem Cell Transplantation/Autologous Bone March row Transplantation - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
carmustine + mercaptopurine + streptozocin - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 48
Peptide vaccine + Poly-ICLC - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Peptide vaccine + Poly-ICLC - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Bendamustine Hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Temozolomide - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Bevacizumab + Radiation Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
RAD001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Aminolevulinic acid - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Procarbazine + Lomustine + Vincristine + Radiation Therapy - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Temozolomide + Radiation Therapy - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Alloreactive Cytotoxic T Lymphocytes + Interleukin-2 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Autologous Tumor Cell Vaccine + Sargramostim + Muromonab-CD3 + Aldesleukin + Radiation Therapy - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 61
Toca 511 + Toca FC - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
AMD3100 + Avastin - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
BIBF 1120 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Oligodendroglioma Therapeutics - Drug Profile Updates 67
Oligodendroglioma Therapeutics - Discontinued Products 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 70
Contact Us 70
Disclaimer 70

List of Tables

Number of Products Under Development for Oligodendroglioma, H2 2011 9
Products under Development for Oligodendroglioma - Comparative Analysis, H2 2011 10
Number of Products under Development by Firms, H2 2011 11
Number of Products under Investigation by Universities/Institutes, H2 2011 13
Number of Products under Investigation by Universities/Institutes, H2 2011 14
Comparative Analysis by Late Stage Development, H2 2011 15
Comparative Analysis by Mid Clinical Stage Development, H2 2011 16
Comparative Analysis by Early Clinical Stage Development, H2 2011 17
Products under Development by Firms, H2 2011 18
Products under Investigation by Universities/Institutes, H2 2011 19
Products under Investigation by Universities/Institutes, H2 2011 20
AstraZeneca PLC, 2011 21
Tocagen Inc, 2011 21
Assessment by Monotherapy Products, H2 2011 22
Assessment by Combination Products 23
Assessment by Stage and Route of Administration, H2 2011 25
Assessment by Molecule Type, H2 2011 27
Oligodendroglioma Therapeutics - Drug Profile Updates 67
Discontinued Products 68

List of Figures

Number of Products under Development for Oligodendroglioma, H2 2011 9
Products under Development for Oligodendroglioma - Comparative Analysis, H2 2011 10
Products under Development by Firms, H2 2011 11
Products under Investigation by Universities/Institutes, H2 2011 12
Late Stage Products, H2 2011 15
Mid Clinical Stage Products, H2 2011 16
Early Clinical Stage Products, H2 2011 17
Assessment by Monotherapy Products, H2 2011 22
Assessment by Combination Products, H2 2011 23
Assessment by Route of Administration, H2 2011 24
Assessment by Stage and Route of Administration, H2 2011 25
Assessment by Molecule Type, H2 2011 26
Assessment by Stage and Molecule Type, H2 2011 27

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Tissue Engineering and Regeneration: Technologies and Global Markets

Tissue Engineering and Regeneration: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • August 2014
  • by BCC Research

This BCC Research report presents an in-depth analysis of the global tissue engineering and regeneration market by technologies, materials, applications segments and regional markets. It includes comprehensive ...

Stem Cells -- 6 Dimensional Assessment (Technical Insights)

Stem Cells -- 6 Dimensional Assessment (Technical Insights)

  • $ 6 500
  • Industry report
  • June 2014
  • by Frost & Sullivan

The clinical translation of regenerative cells The scope of this research service comprises research within the area of adult and embryonic stem cells, and developments in the nascent area of induced pluripotent ...

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus

  • $ 4 995
  • Industry report
  • June 2014
  • by Firstword Pharma

There has been considerable media hype and clinical interest in cancer immunotherapy in recent years. Indeed, there is talk of late stage cancers such as melanoma and NSCLC being managed as chronic conditions ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.